Program
Octreotide
Also written as “Sandostatin LAR Depot”, “Octreotide LAR” and “Sandostatin LAR”.
Its studies are mostly in Acromegaly · Obesity · Diarrhea · Malignant Carcinoid Syndrome · Thymoma, led by 5 companies.
Drug pageOctreotide: every studyMany companies study it; this page follows only the 30 they lead. All 121 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartis | 210 open or running | phase 4since Dec 17, 2002 | Nov 2, 1999 | none ahead |
| Keenova Therapeuticsits history only | 40 open or running | phase 3since Sep 30, 2008 | Sep 30, 2008 | none ahead |
| Chiesi Farmaceuticiits history only | 30 open or running | phase 3since Aug 5, 2011 | Aug 5, 2011 | none ahead |
| Ambrilia Biopharmaits history only | 10 open or running | phase 3since Mar 21, 2008 | Mar 21, 2008 | none ahead |
| Dauntless Pharmaceuticalsits history only | 10 open or running | phase 1since Jan 17, 2017 | Jan 17, 2017 | none ahead |
Also a collaborator on its studies: Quintiles.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Novartis only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 4 studies since Nov 2, 1999.
- Jan 21, 2004Phase 4 study in ObesityNCT00076362 · 60 enrolled · United States
- Oct 14, 2004Phase 2 study in ObesityNCT00094146 · 160 enrolled · United States
- Aug 8, 2005Phase 3 study in AcromegalyNCT00128232 · 100 enrolled
- Sep 7, 2005Phase 2 study in Prostatic NeoplasmsNCT00166725 · 40 enrolled · Italy
- Sep 9, 20052 phase 3 studiesNCT00170742, NCT00225979
- Sep 13, 20052 phase 4 studiesNCT00171886, NCT00171613
- Oct 9, 2005Phase 4 study in AcromegalyNCT00242541 · 50 enrolled · Mexico
- Oct 14, 2005Phase 3 study in Carcinoma, HepatocellularNCT00241020 · 270 enrolled
- Jun 1, 20062 phase 2 studiesNCT00332969, NCT00332696
- Sep 6, 2006Phase 3 study in AcromegalyNCT00372697 · 28 enrolled · Italy
- Sep 13, 2006Phase 4 study in AcromegalyNCT00376064 · 20 enrolled · Germany
- Dec 21, 2007Phase 1 study in Irritable Bowel SyndromeNCT00584298 · 50 enrolled · United States, Canada, Sweden and more
- Dec 21, 2007Phase 3 study in Colorectal NeoplasmsNCT00582426 · 139 enrolled · Brazil
- May 15, 2008Phase 3 study in Carcinoid TumorNCT00690430 · 186 enrolled · United States, Argentina, Austria and more
TargetBeta
“Somatostatin receptor agonist”ChEMBL 37, by rule
Studies
All 21 Novartis leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT00690430Carcinoid Tumor · United States, Argentina, Austria and more | 3 | Completed | Apr 2012 | 186 |
| NCT00584298Irritable Bowel Syndrome · United States, Canada, Sweden and more | 1 | Completed | Apr 2009 | 50 |
| NCT00582426Colorectal Neoplasms · Brazil | 3 | Completed | Sep 2010 | 139 |
| NCT00376064Acromegaly · Germany | 4 | Completed | Jan 2010 | 20 |
| NCT00372697Acromegaly · Italy | 3 | Completed | Oct 2007 | 28 |
| NCT00332969Thymoma · Germany | 2 | Completed | Oct 2010 | 25 |
| NCT00332696Peritoneal Neoplasms · France | 2 | Completed | Sep 2008 | 64 |
| NCT00241020Carcinoma, Hepatocellular | 3 | Completed | Oct 2005 | 270 |
| NCT00242541Acromegaly · Mexico | 4 | Terminated | Aug 2005 | 50 |
| NCT00225979Acromegaly | 3 | Completed | Mar 2005 | 100 |
| NCT00171886Acromegaly · Spain | 4 | Completed | May 2006 | 20 |
| NCT00171613Sexual Infantilism | 4 | Completed | Oct 2005 | 32 |
| NCT00170742Disease · Switzerland | 3 | Terminated | May 2006 | 17 |
| NCT00166725Prostatic Neoplasms · Italy | 2 | Completed | 40 | |
| NCT00128232Acromegaly | 3 | Completed | Aug 2004 | 100 |
| NCT00094146Obesity · United States | 2 | Completed | 160 | |
| NCT00076362Obesity · United States | 4 | Completed | Jul 2005 | 60 |
| NCT00050635Neoplasms · United States | 4 | Completed | 150 | |
| NCT00006269Colorectal Neoplasms · United States | 3 | Terminated | Dec 1999 | 89 |
| NCT00002253Diarrhea · United States | – | Completed | ||
| NCT00002252Diarrhea · United States | – | Completed |
How it is read
Names in the registry
- “Octreotide”, 9 entries
- “Sandostatin LAR Depot”, 3 entries
- “Octreotide LAR”, 3 entries
- “Sandostatin LAR”, 3 entries
- “Octreotide capsules”, 2 entries
Conditions, from the studies’ own filings
- Acromegaly, 17 studies
- Obesity, 2 studies
- Diarrhea, 2 studies
- Malignant Carcinoid Syndrome, 1 study
- Thymoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.